As a revolutionary method, anti-vascular endothelial growth factor (VEGF) therapy has alleviated the condition of patients with wet AMD to a great extent, but some patients do not respond adequately to the therapy [4,5]. The gene discussed is VEGFA; the disease is wet macular degeneration.